Cambridge, United States
Tiba Biotech, founded in 2016, is making strides in the biotechnology sector by leveraging RNA vaccines and therapeutics to enhance gene expression through biodegradable nanoparticle delivery. This pre-clinical stage company, headquartered in Cambridge, Massachusetts, is driven by its mission to create a safer, more affordable generation of nucleic acid products for both human and animal health.
Tiba's revolutionary RNA vaccine platform aims to reimagine existing bio-manufacturing processes, facilitating rapid vaccine development against various diseases. This ambition is backed by substantial strategic alliances, including collaborations with the U.S. Army Medical Research Institute of Infectious Diseases and other prominent research institutions.
Most recently, Tiba secured a $2.00M seed investment in January 2023 from the Coalition for Epidemic Preparedness Innovations, highlighting significant investor confidence in its disruptive potential and strategic direction.
-logo.jpg "Access to Advanced Health Institute (AAHI)"){kind=logo}